Trusted Resources: Education
Scientific literature and patient education texts
Liver Transplantation in Transthyretin Amyloidosis: Characteristics and Management Related to Kidney Disease
source: Transplantation Reviews
year: 2017
authors: Rocha A, Lobato L
summary/abstract:Orthotopic liver transplantation (LT) was implemented as the inaugural disease-modifying therapy for hereditary transthyretin (ATTR) amyloidosis, a systemic amyloidosis mainly affecting the peripheral nervous system and heart. The first approach to pharmacologic therapy was focused on the stabilization of the TTR tetramer; following that new advent LT was assumed as the second step of treatment, for those patients whose neuropathy becomes worse after a course of pharmacologic therapy. The renal disease has been ignored in hereditary ATTR amyloidosis.
The low level of proteinuria or slight renal impairment does not suppose such a heavy glomerular and vascular amyloid deposition. Moreover, severity of renal deposits does not consistently parallel that of myelinated nerve fiber loss. These are pitfalls that limit the success of LT and suggest troublesome criteria for pharmacological therapy or LT. An algorithm of evaluation concerning renal disease and treatment options is presented and some bridges-to-decision are exposed. In stage 4 or 5 kidney disease, the approach remains to deliver combined or sequential liver-kidney transplantation in eligible patients. However, in the majority, hemodialysis is the only option even in the presence of a well-functioning liver graft. In this review, we highlight useful information to aid the transplant hepatologist in the clinical practice.
organization: Hospital de Santo António, Portugal; Centro Hospitalar do Porto, Portugal; Instituto de Ciências Biomédicas, Portugal; University of Porto, PortugalDOI: 10.1016/j.trre.2016.09.002
read more
Related Content
-
Safety and Efficacy of Long-Term Diflunisal Administration in Hereditary Transthyretin (ATTR) AmyloidosisBackground: A recent 2-year randomized ...
-
A Guide to Transthyretin AmyloidosisAmyloidosis is a systemic disorder chara...
-
Dara-CyBorD Treatment – ASG Webinar 1/13https://www.youtube.com/watch?v=4gUXPbOk...
-
Gene Editing Therapy Paves Way for Revolution in Treatment of Genetic DisordersPeople with hereditary transthyretin (AT...
-
CRISPR Gene Editing Reduces Disease-Causing Protein in Hereditary Transthyretin AmyloidosisThe results of the phase 1 study open-la...
-
ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac AmyloidosisTreatment with the investigational drug ...
-
Immunomodulatory Imide Drugs (IMiDs) – ASG Webinar 7/13https://www.youtube.com/watch?v=4gUXPbOk...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.